HAI Book 2025 - Flipbook - Page 166
Gnörich, Johannes
26
Assessment of ATN with a single dynamic [18]F-PI-2620 recording
Johannes Gnörich1,2, Julia Kusche-Palenga1, Agnes Kling1, Artem Zatcepin1,2, Amir Dehsarvi3,
Angela Bronte4, Mirlind Zaganjori1, Lukas Frontzkowski1,3, Sebastian Roemer3,5, Mattes Groß1,
Florian Schöberl5, Maximilian Scheifele1, Theresa Bauer1, Alexander Bernhardt2,5, Alexander
Jäck2,5, Thilo van Eimeren6,7, Alexander Drzezga6,7, Robert Perneczky11, Katharina Bürger3,
Johannes Levin5, Peter Bartenstein1, Osama Sabri10, Henryk Barthel10, Michael Rullmann10,
Sophia Stöcklein8, Günter Höglinger5,9, Nicolai Franzmeier3,9,12, Matthias Brendel1,2,9
1
Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, DE
German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, DE
3
Institute for Stroke and Dementia Research, LMU Munich, Munich, DE
4
Universidad de Navarra, Pamplona, Pamplona, ES
5
Department of Neurology, LMU Munich, Munich, Munich, DE
6
Department of Nuclear Medicine, University Hospital Cologne, Cologne, DE
7
German Center for Neurodegenerative Diseases (DZNE), Bonn, Bonn, DE
8
Department of Radiology, LMU Hospital, Ludwig-Maximilians-University of Munich, Munich, DE
9
Munich Cluster for Systems Neurology (SyNergy), Munich, DE
10
University Hospital Leipzig, Department of Nuclear Medicine, Leipzig, DE
11
Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University,, Munich, DE
12
University of Gothenburg, The Sahlgrenska Academy, Institute of Neuroscience and Physiology, Department of
Psychiatry and Neurochemistry, Mölndal and Gothenburg, SE
2
Patients with neurodegenerative diseases are classified molecularly using the A/T/N classification system. Apart
from fluid biomarkers and structural MRI, the three-dimensional A/T/N system utilizes characteristic features
from amyloid-PET (A), tau-PET (T), and FDG-PET (N), requiring multiple imaging sessions. Thus, we evaluated the
value of dynamic tau-PET with [18F]PI-2620 to assess A/T/N in individual patients during a single imaging session.
Cortical tissue clearance (K2a) of [18F]PI-2620 was validated as a surrogate of the ´-amyloid status against
amyloid-PET and cerebrospinal fluid (CSF) A´42/40 ratio, demonstrating remarkable positive (91.5%) and negative
(95.1%) predictive values at an AUC of 0.99 (P
